Ferrer announces best-in-class results in phase I for Lorediplon in insomnia
The pharmacodynamic effects of a single oral administration of Lorediplon (at 1mg, 5mg and 10mg doses), zolpidem (10mg) and placebo, were assessed in 34 healthy adult subjects employing a phase advanced model of insomnia, in which subjects retire to bed five hours earlier than normal and are required to stay there until early morning. In this model Lorediplon demonstrated dose related clinical benefits in measured sleep parameters that were either comparable to or exceeded zolpidem, in terms of the duration and quality of sleep that subjects achieved. Lorediplon was safe and well tolerated, with no residual effects observed up to 14 hours after dosing.
In addition, Lorediplon has proven safe and well tolerated in the 129 subjects involved in all Phase I clinical studies.
Most read news
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.